Maintenance Risankizumab Sustains Induction Response in Patients with Crohn's Disease in a Randomized Phase 3 Trial. - Ferrante, Marc; Irving, Peter M; Abreu, Maria T; Axler, Jeffrey; Gao, Xiang; Cao, Qian; Fujii, Toshimitsu; Rausch, Astrid; Torres, Joana; Neimark, Ezequiel; Song, Alexandra; Wallace, Kori; et al. (Journal of Crohn's & Colitis, 2024)